Date: 2013-10-15
Type of information: R&D agreement
Compound:
Company: AstraZeneca (UK) TARIS Biomedical (USA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease: bladder cancer
Details: * On October 15, 2013, TARIS Biomedical®, a specialty pharmaceutical company developing innovative, targeted therapies to treat bladder diseases with high unmet medical need, has announced that it has entered into a research collaboration with AstraZeneca to evaluate novel treatments for bladder cancer. Under the terms of the agreement, the companies will work together to evaluate multiple novel cancer therapeutics by employing TARIS’ proprietary bladder delivery platform in combination with targeted cancer therapeutics from AstraZeneca. TARIS’ delivery platform is a soft, flexible system deployed into and retrieved from the bladder using standard urological office procedures. It is designed to provide continuous local delivery to the bladder for days to weeks, depending on the therapeutic application. Furthermore, AstraZeneca has an exclusive option to take a license to the products resulting from the collaboration.
TARIS Biomedical®’s delivery platform is designed to improve treatment by providing controlled, sustained delivery of drug directly to target tissues. TARIS is currently pursuing opportunities in bladder cancer, overactive bladder and Interstitial cystitis. TARIS®’s most advanced product candidate, LiRIS®, is currently in Phase 2 clinical development for the treatment of interstitial cystitis.
Financial terms:
Latest news:
